Clinical Trial Update: Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bevacizumab and lapatinib in children with recurrent or refractory ependymoma has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Cancers
• Ependymoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Lapatinib (Lapatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Brain Cancer, Pediatric Cancers | Phase 2 | Status: COMPLETED | Results posted: 2020-08-26